MediGene concentrates on researching, developing, and commercializing novel drugs in two therapeutic areas: cancer and autoimmune diseases. MediGene is the first German biotech company that has drugs on the market. Until now, our drugs are distributed by partner companies. Medium-term we intend to start our own marketing activities. MediGene has several drug candidates in clinical development, some of which providing substantial sales potential. In addition, we possess innovative platform technologies which enable the search for other therapeutic substances. Licensed products complement our proprietary drug portfolio. This allows us to reduce risks, enhance our opportunities, and excellerate revenue generation.
Further Information
For further information please see our
press releases, have a look at our annual and quarterly reports, or
contact us by phone or e-mail.
MediGene at a glance
founded in 1994 as a Munich Gene Center spin-off
June 2000: IPO, listed on the Frankfurt Stock Exchange
January 2001: acquisition of the US biotechnology company NeuroVir
2004: Acquisition of products and technology of Munich Biotech AG
2006: Acquisition of the British biotechnology company Avidex Limited
about 135 employees
focus on cancer and autoimmune diseases
two drugs on the market
further drug candidates undergoing clinical trials
novel technology platforms
|
|
|
|
|
|
|
|
|
|
|
